Jacques Banchereau, PhD Appointed as Chief Scientific Officer at Javelin Biotech
April 17 2024 - 9:50AM
Business Wire
Javelin Biotech, Inc., a leading technology company specializing
in human tissue chip platforms for biopharma research, is delighted
to announce the appointment of Jacques Banchereau, PhD as its Chief
Scientific Officer (CSO). Banchereau is an internationally
recognized immunologist and molecular biologist, renowned for his
groundbreaking contributions to the field of immunology and drug
discovery.
Over his distinguished 35-year career, Dr. Banchereau has shown
exceptional leadership in both academic and industrial research.
Having held esteemed roles such as Professor and Director of
Immunological Sciences at the Jackson Laboratory for Genomic
Medicine, Chief Scientific Officer at Hoffman-La Roche, CSO at
Immunai, and Adjunct Professor of Immunobiology at Yale School of
Medicine, he has consistently demonstrated his expertise in driving
forward scientific inquiry and pharmaceutical innovation.
In his role at Javelin Biotech, Banchereau will oversee the
company's scientific strategy, leveraging his vast experience and
expertise to drive the development of cutting-edge technology for
the modeling of human diseases. His appointment underscores Javelin
Biotech's commitment to innovation and scientific excellence in the
field of biotechnology.
"We are thrilled to welcome Jacques to the Javelin Biotech
team," said Murat Cirit, PhD, CEO of Javelin Biotech. "His
outstanding achievements and leadership in immunology and drug
discovery make him a valuable addition to our company. We are
confident that his expertise will play a pivotal role in advancing
our research efforts and driving our mission to support the
development of novel treatments for organ-specific diseases."
Banchereau expressed his excitement about joining Javelin
Biotech, stating, "I am honored to be part of a company that is
dedicated to pushing the boundaries of scientific research. Javelin
Biotech's innovative technology has the potential to revolutionize
the way we understand and treat complex diseases, and I look
forward to contributing to its success."
About Javelin Biotech:
Javelin Biotech is a biotechnology company focused on humanizing
preclinical drug discovery with a predictive platform that merges
human tissue chips with digital twin technology to develop better
medicines faster. The Javelin platform enables the creation of
accurate and physiologically relevant models of human tissues,
providing valuable insights into disease mechanisms and drug
responses, allowing biopharmaceutical companies to reduce their
reliance on animal studies and develop better drugs faster.
For more information, visit www.javelinbiotech.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240417237133/en/
Kevin O’Handley media@javelinbio.com (781) 995-3099